• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓灰质炎病毒疫苗株作为黏膜疫苗载体及其在开发艾滋病疫苗方面的潜在用途。

Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.

作者信息

Crotty Shane, Andino Raul

机构信息

Department of Microbiology and Immunology, University of California, 513 Parnassus Ave., Box 0414, San Francisco, CA 94143, USA.

出版信息

Adv Drug Deliv Rev. 2004 Apr 19;56(6):835-52. doi: 10.1016/j.addr.2003.10.042.

DOI:10.1016/j.addr.2003.10.042
PMID:15063593
Abstract

Sexual transmission is the major route for the spread of the human immunodeficiency virus (HIV) in the AIDS pandemic progression. Most attempts to develop a protective HIV vaccine have failed despite eliciting strong systemic immune responses. The basic hypothesis of our poliovirus vaccine vector strategy is that essential requirements for protective immunization against HIV and other related lentiviruses may involve (1) induction of mucosal immunity and (2) immunological responses against multiple viral antigens. To test this hypothesis, we have developed replication-competent poliovirus recombinants, based on the Sabin poliovirus vaccine strain viruses, that carry and express antigens derived from the simian immunodeficiency virus (SIV). Because there are no good immunological correlates for complete protection against SIV infection, we have elected to express the entire SIV genome in defined, discrete overlapping fragments. With this approach all the potentially important antigenic sequences can be effectively expressed at local mucosal sites by the inoculation of a cocktail of recombinant polioviruses that carries a complete set of SIV antigens. Infection of susceptible mice and cynomolgus monkeys with poliovirus-SIV cocktails elicits serum and secretory humoral responses, as well as a strong cellular immunity to the inserted sequences. Most importantly, we have demonstrated that vaccination of cynomolgus monkeys with poliovirus-SIV cocktails protects against infection and AIDS after intravaginal challenge with highly pathogenic SIV(mac)251.

摘要

性传播是人类免疫缺陷病毒(HIV)在艾滋病大流行进程中传播的主要途径。尽管能引发强烈的全身免疫反应,但大多数研发保护性HIV疫苗的尝试都失败了。我们脊髓灰质炎病毒疫苗载体策略的基本假设是,针对HIV和其他相关慢病毒进行保护性免疫的基本要求可能包括:(1)诱导黏膜免疫;(2)针对多种病毒抗原的免疫反应。为了验证这一假设,我们基于Sabin脊髓灰质炎病毒疫苗株病毒开发了具有复制能力的脊髓灰质炎病毒重组体,这些重组体携带并表达源自猴免疫缺陷病毒(SIV)的抗原。由于目前尚无针对完全预防SIV感染的良好免疫相关指标,我们选择将整个SIV基因组以特定的、离散的重叠片段形式进行表达。通过这种方法,接种携带全套SIV抗原的重组脊髓灰质炎病毒混合物,所有潜在重要的抗原序列都能在局部黏膜部位有效表达。用脊髓灰质炎病毒 - SIV混合物感染易感小鼠和食蟹猴会引发血清和分泌性体液反应,以及对插入序列的强烈细胞免疫。最重要的是,我们已经证明,用脊髓灰质炎病毒 - SIV混合物对食蟹猴进行疫苗接种后,在经阴道用高致病性SIV(mac)251攻击时可预防感染和艾滋病。

相似文献

1
Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.脊髓灰质炎病毒疫苗株作为黏膜疫苗载体及其在开发艾滋病疫苗方面的潜在用途。
Adv Drug Deliv Rev. 2004 Apr 19;56(6):835-52. doi: 10.1016/j.addr.2003.10.042.
2
The prospective preventative HIV vaccine based on modified poliovirus.基于改良脊髓灰质炎病毒的前瞻性预防性艾滋病毒疫苗。
Med Hypotheses. 2007;68(6):1258-61. doi: 10.1016/j.mehy.2006.07.062. Epub 2006 Dec 28.
3
Adenoviruses as vectors for HIV vaccines.腺病毒作为HIV疫苗的载体。
AIDS Rev. 2003 Jul-Sep;5(3):178-85.
4
Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.使用萨宾脊髓灰质炎病毒载体预防猿猴免疫缺陷病毒阴道感染
J Virol. 2001 Aug;75(16):7435-52. doi: 10.1128/JVI.75.16.7435-7452.2001.
5
Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.编码猿猴免疫缺陷病毒gag基因和人类免疫缺陷病毒env基因的5型/35型嵌合腺病毒载体可使猴子对猿猴/人类免疫缺陷病毒产生保护性免疫。
Virology. 2007 Oct 25;367(2):390-7. doi: 10.1016/j.virol.2007.06.012. Epub 2007 Jul 12.
6
Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.由异源弹状病毒初免-加强免疫方法诱导的强烈细胞和体液抗HIV Env免疫反应。
Virology. 2005 Jan 5;331(1):82-93. doi: 10.1016/j.virol.2004.10.018.
7
Mucosal responses to parenteral and mucosal vaccines.对肠胃外和粘膜疫苗的粘膜反应。
Dev Biol Stand. 1998;95:141-6.
8
Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.用肠道腺病毒41型载体进行口服致敏增强肠道细胞免疫诱导
J Virol. 2009 Jan;83(2):748-56. doi: 10.1128/JVI.01811-08. Epub 2008 Nov 5.
9
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.携带载体的Gag和Env而非Tat在Mamu - A*01阴性恒河猴中对猿猴 - 人类免疫缺陷病毒89.6P攻击显示出有效性。
J Virol. 2005 Oct;79(19):12321-31. doi: 10.1128/JVI.79.19.12321-12331.2005.
10
Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.评估禽痘病毒-痘苗病毒初免-加强疫苗策略以获得针对HIV-1的高水平黏膜和全身免疫。
Vaccine. 2006 Jul 26;24(31-32):5881-95. doi: 10.1016/j.vaccine.2006.04.023. Epub 2006 May 2.

引用本文的文献

1
Comparative Evaluation of Prophylactic SIV Vaccination Modalities Administered to the Oral Cavity.口腔途径预防性 SIV 疫苗接种方式的比较评估。
AIDS Res Hum Retroviruses. 2020 Dec;36(12):984-997. doi: 10.1089/AID.2020.0157. Epub 2020 Oct 27.
2
Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses.用活重组鼻病毒进行黏膜疫苗接种,随后进行皮内DNA给药,可引发强效且具有保护性的HIV特异性免疫反应。
Sci Rep. 2016 Nov 17;6:36658. doi: 10.1038/srep36658.
3
Nonhomologous recombination between defective poliovirus and coxsackievirus genomes suggests a new model of genetic plasticity for picornaviruses.
缺陷型脊髓灰质炎病毒与柯萨奇病毒基因组之间的非同源重组为微小核糖核酸病毒的遗传可塑性提出了一种新模型。
mBio. 2014 Aug 5;5(4):e01119-14. doi: 10.1128/mBio.01119-14.
4
Development of replication-competent viral vectors for HIV vaccine delivery.用于 HIV 疫苗递送的复制型病毒载体的开发。
Curr Opin HIV AIDS. 2013 Sep;8(5):402-11. doi: 10.1097/COH.0b013e328363d389.
5
Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.口服柯萨奇病毒 B4 重组体诱导黏膜 HIV 特异性 B 和 T 细胞应答。
Vaccine. 2012 May 21;30(24):3666-74. doi: 10.1016/j.vaccine.2012.03.034. Epub 2012 Mar 29.
6
Current progress in the development of a prophylactic vaccine for HIV-1.HIV-1预防性疫苗研发的当前进展。
Drug Des Devel Ther. 2010 Dec 22;5:9-26. doi: 10.2147/DDDT.S6959.
7
Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.将抗原包裹入腺病毒衣壳蛋白以用于疫苗策略。
Mol Pharm. 2011 Feb 7;8(1):3-11. doi: 10.1021/mp100214b. Epub 2010 Dec 1.
8
Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.口服免疫一种活柯萨奇病毒/艾滋病毒重组体可诱导 gag p24 特异性 T 细胞应答。
PLoS One. 2010 Sep 2;5(9):e12499. doi: 10.1371/journal.pone.0012499.
9
Characterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery.用于阴道给药的高度结构化凝胶平台的流变学、粘膜粘附性和药物释放特性的表征。
Biomacromolecules. 2009 Sep 14;10(9):2427-35. doi: 10.1021/bm9003332.
10
Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector.柯萨奇病毒B载体中HIV-1序列的包装限制和稳定性
Vaccine. 2009 Jun 19;27(30):3992-4000. doi: 10.1016/j.vaccine.2009.04.035. Epub 2009 May 3.